The effect of transversus abdominis plane block with Ropivacaine on postoperative pain

Comparing the efficacy of standard spinal anesthesia and transversus abdominis plane block with Ropivacaine 0.5% on relieving the postoperative pain after laparoscopic gynecologic surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190204042618N3

Enrollment

200

Registered

2019-03-31

Start date

2016-05-19

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after laparoscopic gynecologic surgery.

Interventions

Intervention 1: Intervention group: In this group, in addition to standard spinal anesthesia, an anesthetic drug Ropivacaine (Naropin,0.5%) was injected at a dose of 0.5 mg / kg between transverse abd

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Candidate for laparoscopic gynecologic surgery (such as ovarian cystectomy and hysterectomy) Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Having a history of allergy to the agents used in the study suffering from acute and/or chronic preoperative pains

Design outcomes

Primary

Measure	Time frame
Severity of pain. Timepoint: At the time of recovery, 30 minutes, 2, 4, 6, 12, and 48 hours after surgery. Method of measurement: VAS (Visual analogue scale).;Severity of nausea and vomiting. Timepoint: At the time of recovery, 30 minutes, 2, 4, 6, 12, and 48 hours after surgery. Method of measurement: Based on questionnaire and its scoring (0 = no nausea and vomiting, 1 = mild, 2 = moderate and 3 = severe).	—

Measure

Time frame

Severity of pain. Timepoint: At the time of recovery, 30 minutes, 2, 4, 6, 12, and 48 hours after surgery. Method of measurement: VAS (Visual analogue scale).;Severity of nausea and vomiting. Timepoint: At the time of recovery, 30 minutes, 2, 4, 6, 12, and 48 hours after surgery. Method of measurement: Based on questionnaire and its scoring (0 = no nausea and vomiting, 1 = mild, 2 = moderate and 3 = severe).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtoullah Ghahiri

Esfahan University of Medical Sciences

ghahiri@med.mui.ac.ir+98 31 1668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026